CNS Pharmaceuticals vs Monopar Therapeutics
CNSP and MNPR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CNSP and MNPR compare
Monopar Therapeutics is the larger company, worth 114 times as much as CNS Pharmaceuticals ($483M against $4.2M).
Monopar Therapeutics scores higher on the StockData Score (7 against 5 for CNS Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CNSP | MNPR |
|---|---|---|
| Size and price | ||
| Market cap | $4.2M | $483M |
| Share price | $2.89 | $72.00 |
| Change, 1 year | −56.1% | −12.8% |
| Change, 5 years | −100.0% | 206% |
| Beta (5Y) | 1.63 | 0.78 |
| Employees | 8 | 22 |
| StockData Score | ||
| Total score | 5 | 7 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 4 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 0.2× (better) | 3.8× |
| Profitability | ||
| Return on equity | −107% | −15.3% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | −1131.6× | – |
| Current ratio | 5.86 | 43.55 (better) |
| Altman Z-score | −7.75 | 90.53 (better) |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 19.2% | 92.7% |
| Held by insiders | 26.5% | – |
| Insider net buying, 12 months | $44.0K (better) | −$5.6M |
| Short interest, % of float | 0.15% | – |
Go deeper
- CNSP stock overview
- CNSP income statement
- CNSP valuation and score
- MNPR stock overview
- MNPR income statement
- MNPR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.